Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. by Volkmann, Elizabeth R et al.
UCLA
UCLA Previously Published Works
Title
Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in 
two independent cohorts.
Permalink
https://escholarship.org/uc/item/2tb0h2wh
Journal
BMJ open gastroenterology, 4(1)
ISSN
2054-4774
Authors
Volkmann, Elizabeth R
Hoffmann-Vold, Anna-Maria
Chang, Yu-Ling
et al.
Publication Date
2017
DOI
10.1136/bmjgast-2017-000134
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Systemic sclerosis is associated with
specific alterations in gastrointestinal
microbiota in two independent cohorts
Elizabeth R Volkmann,1 Anna-Maria Hoffmann-Vold,2 Yu-Ling Chang,3
Jonathan P Jacobs,1 Kirsten Tillisch,1 Emeran A Mayer,1 Philip J Clements,1
Johannes R Hov,4,5,6 Martin Kummen,4,5 Øyvind Midtvedt,2,6 Venu Lagishetty,1
Lin Chang,1 Jennifer S Labus,1 Øyvind Molberg,2 Jonathan Braun3
To cite: Volkmann ER,
Hoffmann-Vold A-M,
Chang Y-L, et al. Systemic
sclerosis is associated with
specific alterations in
gastrointestinal microbiota in
two independent cohorts.
BMJ Open Gastro 2017;3:
e000134. doi:10.1136/
bmjgast-2017-000134
▸ Additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjgast-2017-
000134)
ERV and A-MH-V shared first
authorship.
Received 20 January 2017
Revised 16 March 2017
Accepted 20 March 2017
For numbered affiliations see
end of article.
Correspondence to
Dr Elizabeth R Volkmann;
evolkmann@mednet.ucla.edu
ABSTRACT
Objective: To compare faecal microbial composition
in patients with systemic sclerosis (SSc) from 2
independent cohorts with controls and to determine
whether certain genera are associated with SSc-
gastrointestinal tract (GIT) symptoms.
Design: Adult patients with SSc from the University of
California, Los Angeles (UCLA) and Oslo University
Hospital (OUH) and healthy controls participated in this
study (1:1:1). All participants provided stool specimens
for 16S rRNA sequencing. Linear discriminant analysis
effect size demonstrated genera with differential
expression in SSc. Differential expression analysis for
sequence count data identified specific genera
associated with GIT symptoms as assessed by the GIT
2.0 questionnaire.
Results: The UCLA-SSc and OUH-SSc cohorts were
similar in age (52.1 and 60.5 years, respectively),
disease duration (median (IQR): 6.6 (2.5–16.4) and 7.0
(1.0–19.2) years, respectively), gender distribution
(88% and 71%, respectively), and GIT symptoms
(mean (SD) total GIT 2.0 scores of 0.7 (0.6) and 0.6
(0.5), respectively). Principal coordinate analysis
illustrated significant microbial community differences
between SSc and controls (UCLA: p=0.001; OUH:
p=0.002). Patients with SSc had significantly lower
levels of commensal genera deemed to protect against
inflammation, such as Bacteroides (UCLA and OUH),
Faecalibacterium (UCLA), Clostridium (OUH); and
significantly higher levels of pathobiont genera, such
as Fusobacterium (UCLA), compared with controls.
Increased abundance of Clostridium was associated
with less severe GIT symptoms in both cohorts.
Conclusions: The present analysis detected specific
aberrations in the lower GIT microbiota of patients with
SSc from 2 geographically and ethnically distinct
cohorts. These findings suggest that GIT dysbiosis
may be a pathological feature of the SSc disease state.
INTRODUCTION
The majority of patients with systemic scler-
osis (SSc) experience gastrointestinal tract
(GIT) dysfunction.1 2 Symptoms of lower
GIT involvement3 adversely affect quality of
life and social functioning.4 5 Unfortunately,
no effective treatment options exist for elim-
inating these disruptive symptoms, largely
because the pathogenesis of this dimension
of SSc is poorly understood.
GIT dysbiosis occurs in a number of
chronic inflammatory conditions, including
inflammatory bowel disease (IBD),6–9 and
Summary box
What is already known about this subject?
▸ Gastrointestinal tract dysfunction affects over
90% of patients with systemic sclerosis.
▸ The pathogenesis of lower gastrointestinal tract
dysfunction in systemic sclerosis is largely
unknown.
▸ Emerging evidence suggest that gastrointestinal
tract dysbiosis may be a feature of the systemic
sclerosis disease state.
What are the new findings?
▸ The study found specific alterations in the
gastrointestinal microbiota in two independent
systemic sclerosis cohorts.
▸ The extent of dysbiosis (ie, alterations in the
intestinal microbiota) appeared greatest in
patients from the American systemic sclerosis
cohort compared with those from the Norwegian
systemic sclerosis cohort.
▸ Specific genera were associated with severity of
gastrointestinal tract symptoms.
How might it impact on clinical practice in
the foreseeable future?
▸ Currently, few effective treatment options exist
for managing lower gastrointestinal tract symp-
toms in patients with systemic sclerosis. If spe-
cific genera are found to contribute the
gastrointestinal tract phenotype in systemic
sclerosis, such genera could provide specific
targets for intervention to avert or treat this
important clinical dimension of systemic
sclerosis.
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recent studies suggest that alterations in GIT microbiota
may be a feature of the SSc disease state.3 10 Our prior
study demonstrated that patients with SSc had decreased
abundance of beneficial human commensal genera
known to produce key energy metabolites and anti-
inflammatory molecules for mucosal health (eg,
Faecalibacterium; Clostridium) with a concurrent increase
in potential pathobiont genera (eg, invasive γ
Proteobacteria; Fusobacterium), compared with controls.10
This study also demonstrated that increased abun-
dance of Clostridium and decreased abundance of
Fusobacterium were independently associated with
decreased GIT symptoms.10 To further explore whether
alterations in microbial composition may serve as a
pathogenic factor in SSc-GIT dysfunction, the present
study examined the lower GIT microbiota from two
independent SSc cohorts. Whereas our prior study
examined colonic mucosal microbes via colonoscopy,
the present study examined stool specimens from the
same patients with SSc.10 Assessment of stool specimens
may reflect other aspects of the gut microbiota (eg,
metabolic features) and can be obtained by a less inva-
sive approach.
The objectives of this study, not previously explored in
the SSc literature, were to: (1) establish whether analysis
of stool specimens can distinguish the GIT microbiota of
patients with SSc versus healthy controls; (2) compare
the GIT microbiota of patients with SSc from two geo-
graphically independent cohorts; and (3) evaluate the
hypothesis that specific microbial genera are associated
with SSc-GIT symptom severity.
MATERIALS AND METHODS
Study participants
Patient participants were consecutively enrolled from
the outpatient rheumatology clinics at University of
California, Los Angeles (UCLA) and Oslo University
Hospital (OUH). Eligible participants included adult
(≥18 years) patients with SSc according to the 2013
American College of Rheumatology/European League
Against Rheumatism Classification Criteria for SSc.11
Exclusion criteria included IBD, inability to withstand
from taking an antibiotic and a probiotic for at least
3 weeks prior to the stool collection. Patients were
allowed to continue taking a proton pump inhibitor
medication because this agent exerts negligible effects
on colonic microbiota.12
Healthy controls stool specimens were obtained from
the UCLA Specialized Center of Research in
Neurovisceral Sciences and Women’s Health Repository,
which consists of stool specimens from healthy adult par-
ticipants (12 men and 9 women) who do not have GIT
symptoms. These control participants were different
than the control participants used in our prior study.10
We attempted to match 17 of these healthy participants
by age and sex with the UCLA-SSc cohort patients (1:1);
however, the healthy control cohort had more men than
women so gender matching was not always possible.
These healthy controls specimen also served as the con-
trols for the OUH-SSc cohort.
The UCLA Institutional Review Board and the
Regional Committee of Health and Medical Research
Ethics in Norway approved the study protocol and written
informed consent was obtained from each participant.
Specimen procurement and processing
Participants at both sites collected stool specimens using
our previously published, standard collection method13
and immediately froze the specimen. Frozen specimens
were subsequently transferred on ice to the participant’s
study centre and stored at −80°C. OUH specimens were
shipped overnight on dry ice to UCLA for further process-
ing. Please see the online supplementary appendix for
complete details of specimen procurement and processing.
16S rRNA gene sequencing and microbial composition
analysis
The microbiota from the stool specimens were profiled
by multiplex sequencing for bacterial rRNA genes using
an Illumina HiSeq 2500 (Illumina, San Diego,
California, USA) sequence technique. All samples
(UCLA-SSc, OUH-SSc, controls) were analysed simultan-
eously at UCLA to avoid any batch effects. The exact
details of this approach have been outlined in our prior
publication,9 10 and are summarised in the online
supplementary appendix.
Faecal calprotectin
Faecal calprotectin concentrations were measured in
duplicate from the stool specimens of the UCLA-SSc
and healthy control participants using a commercial kit
(KTR-849, Epitope Diagnostics, San Diego, California,
USA) according to the manufacturer’s instructions.
Assessment of GIT symptoms
On the day of their stool collection, the UCLA and
OUH-SSc participants completed the GIT 2.0, a valid
measure of GIT symptom severity in patients with SSc.14
The questionnaire consists of seven domains and has
been translated and validated in several languages,
including Norwegian. scores on the GIT 2.0 can indicate
self-rated severity (ie, none/mild vs moderate vs severe/
very severe disease) of GIT involvement based on previ-
ously published score thresholds.14
Statistical and bioinformatics analyses
Statistical approach
Analyses were performed using R V.3.1.2. Mean and SDs
were used to describe continuous parametric data;
median and IQRs were used to describe continuous
non-parametric data. All tests were two-sided with a 0.05
α level. To compare the microbial communities of SSc
versus control samples, α and β diversity were analysed.
The α diversity represents the complexity of composition
within members of a group, and β diversity represents
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the between-participant similarity of microbial compos-
ition and enables the identification of differences
between samples within a group. We also examined taxo-
nomic differences at specific levels (ie, phylum, genus)
using linear discriminant analysis effect size (LefSe). We
used the false discovery rate (FDR) of Benjamini and
Hochberg,15 and a significant association was defined at
the FDR q-value ≤0.1. Please see the online
supplementary appendix for further details.
RESULTS
Participant characteristics
Seventeen UCLA-SSc cohort patients (88% women;
median age 52.1 years) and 17 OUH-SSc cohort patients
(71% women; median age 60.5 years) were enrolled
(table 1). The healthy control cohort (N=17) was
younger than the SSc cohorts (median age 29.0 years),
and had a predominance of women (60% women). The
OUH-SSc cohort was mostly Caucasian (94%); whereas
the UCLA-SSc and healthy control cohorts had more
Hispanics (35% and 24%, respectively, vs 6% in the
OUH-SSc cohort). The mean body mass index (BMI)
was similar in the two SSc cohorts (∼24 for both
cohorts) and slightly higher in the controls (28.1),
although the difference in BMI between SSc participants
and healthy controls was not significant.
UCLA-SSc and OUH-SSc cohort patients had similar
SSc disease durations, proportion of patients with diffuse
cutaneous sclerosis, and autoantibody profiles (table 1).
Table 1 SSc participant characteristics
UCLA-SSc participants (N=17) OUH-SSc participants (N=17)
Age (years) Median 52.1 (IQR 46.6–63.0) 60.5 (IQR 46.0–71.0)
Female 15 (88.2%) 12 (70.6%)
Race
White 9 (52.9%) 16 (94.1%)
Asian 2 (11.8%) 0
More than one race 4 (23.5%) 0
Other 2 (11.8%) 0
Hispanic 6 (35.3%) 1 (5.9%)
BMI 24.0 (4.2) 24.5 (3.6)
Diffuse cutaneous disease 6 (35.3%) 7 (41.2%)
SSc disease duration (years) Median 6.6 (IQR 2.5–16.4) Median 7.0 (IQR 1.0–19.2)
Early SSc (<3 years) 4 (23.5%) 7 (41.2%)
ANA positive 15/16 (93.8%) 17/17 (100%)
Scl-70 positive 3/11 (27.3%) 4/17 (23.5%)
Anticentromere positive 5/11 (45.5%) 9 (52.9%)
HRCT-defined interstitial lung disease 12/17 (70.6%) 8/17 (47.1%)
Current prednisone use* 3 (17.6%) 2 (11.8%)
Current other immunosuppressant use† 6 (35.3%) 2 (11.8%)
Current use of probiotic oral supplement‡ 3 (17.6%) 3 (17.6%)
Current use of proton pump inhibitor 10 (58.8%) 5 (29.4%)
Current SSc disease activity
MRSS>18 3 (17.6%) 5 (29.4%)
Increase in MRSS 2 (11.8%) 3 (17.6%)
Digital ulcers 4 (23.5%) 4 (23.5%)
Tendon friction rubs 2 (11.8%) 3 (17.6%)
DLCO<70% predicted 10 (58.8%) 8 (47.1%)
GIT 2.0 total score Mean 0.7 (0.6)§ Mean 0.6 (0.5)§
Distension/bloating Mean 1.5 (0.9)§ Mean 1.2 (0.8)§
Diarrhoea Mean 0.4 (0.6)¶ Mean 0.3 (0.3)¶
Faecal soilage Mean 0.5 (0.9)¶ Mean 0.3 (0.6)¶
Constipation Mean 0.7 (0.7)§ Mean 0.6 (1.1)§
Emotional well-being Mean 0.5 (0.7)§ Mean 0.5 (0.7)§
Social functioning Mean 0.5 (0.5)§ Mean 0.4 (0.6)¶
Values are n (%), except where otherwise noted.
*Dosages of prednisone were ≤10 mg daily.
†Immunosuppressant medications used included mycophenolate (UCLA: N=1; OUH: N=2) and azathioprine (UCLA: N=2).
‡Probiotic used in the UCLA-SSc cohort included culturelle (N=1), florify (N=1) and align (N=1). For the OUH-SSc cohort, patients consumed
probiotic enriched sour milk products (N=3). Probiotics were not consumed within 3 weeks of the stool collection.
§Score indicates moderate symptom severity.14
¶Score indicates mild symptom severity.14
ANA, anti-nuclear antibody; BMI, body mass index; DLCO, diffusing capacity for carbon monoxide; GIT, gastrointestinal tract; HRCT,
high-resolution CT; MRSS, Modified Rodnan Skin Score; OUH, Oslo University Hospital; SSc, systemic sclerosis; UCLA, University of
California, Los Angeles.
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However, more patients in the UCLA-SSc cohort (71%)
had clinically significant interstitial lung disease (ILD)
by high-resolution CT,16 compared with the OUH-SSc
cohort (47%).
The UCLA-SSc and OUH-SSc cohorts also had similar
GIT symptom profiles (table 1). The mean GIT 2.0
scores indicated moderate symptom severity14 for the
total score, as well as for the following domains: disten-
sion/bloating, emotional well-being and constipation
(table 1). The mean GIT 2.0 scores for faecal soilage
and diarrhoea indicated mild symptom severity14
(table 1). Six UCLA-SSc participants (35%) had taken
antibiotics in the 3 months preceding stool collection;
the mean time between cessation of antibiotics and stool
collection was 6.5 weeks (range 4–12 weeks). None of
the OUH-SSc cohort patients had taken antibiotics
3 months prior to stool sampling.
Only three of the UCLA-SSc cohort patients had ele-
vated levels of faecal calprotectin, which was defined as
>50 μg/g. None of the control participants had elevated
levels of faecal calprotectin.
Colonic microbial diversity in SSc
After the operational taxonomic unit (OTU) selection
process, a total of 231, 250 and 184 species-level OTUs
were generated from the UCLA-SSc, OUH-SSc and
healthy control cohorts, respectively. The α diversity
(ie, the complexity of microbial composition) was
similar between the UCLA-SSc and control participants
(see online supplementary figure S1) and between the
OUH-SSc and control participants (see online
supplementary figure S2). There were also no significant
differences in α diversity between the UCLA-SSc and
OUH-SSc participants (see online supplementary
figure S3).
The β diversity was then computed to determine
whether SSc and control participants differed in their
microbial composition. The principle coordinate ana-
lysis visualisation of the weighted Unifrac distances and
analysis of variance using distance matrices (Adonis) of
this comparison are shown in figure 1. In the UCLA-SSc
(R2 0.355; p=0.001) and the OUH-SSc (R2 0.126;
p=0.002) cohorts, the microbial composition among
patients with SSc was significantly different than healthy
controls. The magnitude of this difference appeared
greater between the UCLA-SSc cohort and healthy con-
trols than between the OUH-SSc cohort and healthy
controls based on the R2 values and as illustrated in
figure 1. The β diversity also differed between the
UCLA-SSc and OUH-SSc cohort patients (R2 0.145;
p=0.002).
Colonic microbial genera are differentially abundant in
patients with SSc
To begin to define the compositional differences
between patients with SSc and healthy controls pre-
dicted by the β diversity analysis, the relative abundances
of microbial composition at different taxonomic levels
were computed (figure 2). The two predominant phyla
in SSc samples were Bacteroidetes (UCLA: 21.3%; OUH:
45.0%; controls: 63.2%), and Firmicutes (UCLA: 63.5%;
OUH: 42.8%; controls: 33.0%). The relative abundance
of Bacteroidetes was significantly decreased in the
UCLA-SSc cohort compared with the healthy control
cohort (p<0.0001) and in the OUH-SSc cohort com-
pared with the healthy control cohort (p=0.009).
LefSe multivariate analysis demonstrated significant
taxonomic differences between SSc and healthy controls
at the genus level for the UCLA-SSc (figure 3) and
OUH-SSc (figure 4) cohorts. The LefSe analysis compar-
ing the UCLA-SSc and healthy control cohorts yielded
Figure 1 Significant differences
in the β diversity of the SSc and
healthy samples as demonstrated
by principal coordinate analysis
plots of the weighted UniFrac
distance. Each dot represents a
sample from a UCLA-SSc cohort
patient (open circle) or a healthy
control (closed circle). Each star
represents a sample from a
OUH-SSc cohort patient. The p
values provided were calculated
by analysis of variance using
distance matrices. OUH, Oslo
University Hospital; PCoA,
principle coordinate analysis;
SSc, systemic sclerosis; UCLA,
University of California, Los
Angeles.
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more significant genus-level differences than the analysis
comparing the OUH-SSc and healthy control cohorts.
Commensal genera such as Faecalibacterium (UCLA),
Clostridium (OUH) and Bacteroides (UCLA, OUH) were
depleted in patients with SSc; whereas, Fusobacterium
(UCLA), Ruminococcus (UCLA) and the uncommon
γ-Proteobacteria, Erwinia (UCLA), were enriched in
patients with SSc, compared with health controls.
Consistent with our prior study,10 Lactobacillus (consid-
ered to be a commensal genus17) was found in greater
abundance in patients with SSc compared with controls
in the UCLA and OUH cohorts (figures 3 and 4).
When comparing the UCLA-SSc and OUH-SSc
cohorts, the LefSe analysis revealed that specific com-
mensal genera, including Faecalibacterium and Bacteroides,
were significantly more abundant in the OUH-SSc cohort
patients compared with the UCLA-SSc cohort patients
(fold change scores of 4.85 and 3.75, respectively).
Specific microbial genera and species are associated with
SSc-GIT symptoms
Differential expression analysis for sequence count data
multivariate analysis identified specific microbial genera
associated with SSc-GIT symptom severity based on the
scores for the total GIT 2.0 and individual domains (eg,
constipation, diarrhoea or distension/bloating). For the
total score and each domain, patients were dichotomised
into low (none-to-mild) or high (moderate-to-severe)
GIT symptom severity groups, and the fold change and
q-values for organisms reaching significance were
tabulated (see online supplementary table S1). The fre-
quency of distribution of patients in each disease severity
category were fairly well balanced (N for low vs high
groups): total score (18 vs 16); constipation (16 vs 18);
distention/bloating (8 vs 26) and diarrhoea (18 vs 15).
In both SSc cohorts, Clostridium was more abundant in
patients with low GIT symptom severity (for the total GIT
score and the bloating/distension domain) compared
with patients with high GIT symptom severity (figure 5
and see online supplementary table S1). Lactobacillus was
more abundant in patients with none-to-mild constipa-
tion compared with patients with moderate-to-severe con-
stipation. In contrast, Prevotella was more abundant
in patients with moderate-to-severe GIT symptom
severity (bloating/distention domain, diarrhoea domain)
compared with patients with none-to-mild GIT symptom
severity.
DISCUSSION
Consistent with our prior findings,10 the present study
demonstrated that the SSc disease state is associated with
alterations in the GIT microbial consortium. Using data
from two independent SSc cohorts, we found that spe-
cific faecal microbial taxa were enriched or depleted
among patients with SSc compared with healthy controls.
We also demonstrated that specific taxa were associated
with severity of GIT symptoms in both SSc cohorts.
In terms of phylum-level differences, the relative abun-
dance of Bacteroidetes was significantly decreased in the
Figure 2 Microbial composition at the phylum level in UCLA-SSc samples (top left), OUH-SSc samples (top right) and healthy
samples (bottom left). Legend provides colour coding specific to each phylum. OUH, Oslo University Hospital; SSc, systemic
sclerosis; UCLA, University of California, Los Angeles.
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UCLA and OUH-SSc cohorts compared with the healthy
control cohort. This finding is of interest in light of the
recent evidence suggesting that the ratio of Firmicutes to
Bacteroidetes may have an important effect on human
health.18 19 Patients with SSc in the UCLA cohort had
the lowest proportion of Bacteroidetes (21.3%), followed
by patients with SSc in the OUH cohort (45.0%) and
healthy controls (63.2%).
Figure 3 Genus-level taxa
associated with UCLA-SSc cohort
patients versus healthy
particiapnts. LefSe multivariate
analysis was used to identify
significant associations (q<0.1),
and LDA was used to calculate
the effect size for these
associations. Negative and
positive effect sizes denote
genera decreased (blue) or
increased (red) in patients with
SSc, respectively. All genera with
an absolute LDA score >2.5 were
included in this figure. LDA, linear
discriminant analysis; LefSe,
linear discriminant analysis effect
size; SSc, systemic sclerosis;
UCLA, University of California,
Los Angeles.
Figure 4 Genus-level taxa
associated with OUH-SSc cohort
patients versus healthy
participants. LefSe multivariate
analysis was used to identify
significant associations (q<0.1),
and LDA was used to calculate
the effect size for these
associations. Negative and
positive effect sizes denote
genera decreased (blue) or
increased (red) in patients with
SSc, respectively. All genera with
an absolute LDA score >2.5 were
included in this figure. LDA, linear
discriminant analysis; LefSe,
linear discriminant analysis effect
size; OUH, Oslo University
Hospital; SSc, systemic sclerosis.
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Consistent with the observed decrease in Bacteroidetes,
lower level taxonomic analysis revealed that both SSc
cohorts had significantly lower levels of the commensal
genera Bacteroides, which is thought to protect the host
from mucosal inflammation and against colonisation of
pathogenic species. Low relative abundance of Bacteroides
is associated with increased disease activity in other
chronic inflammatory diseases, such as Crohn’s disease
(CD).20 The fold change scores for the UCLA-SSc and
OUH-SSc cohorts relative to controls was nearly 5 signi-
fying a substantial shift in this genus in the SSc disease
state.
Concordant with our prior study using colonic lavage
specimens,10 we found that Faecalibacterium (UCLA) and
Clostridium (OUH) were also depleted in SSc. Low abun-
dance of these genera is associated with increased
disease activity in IBD.21–23 As Clostridium species have
been found to induce the expansion of regulatory T
cells,24 it is tempting to speculate that depletion of these
taxa may reduce the number of regulatory T cells, which
may play a role in SSc pathogenesis.25 It is important to
note, however, that species within this genus vary in
terms of their metabolic properties. Future studies may
explore the relationship between the abundance of spe-
cific species within the Clostridium genus and levels of
circulating regulatory T cells.
In line with the potential immunoregulatory proper-
ties of Clostridium, we found that increased abundance of
this genus was associated with decreased GIT symptoms
(for the total GIT symptom severity score and the bloat-
ing/distension domain score). Our prior study also
reported a link between Clostridium and GIT symptoms.10
If future studies demonstrate that Clostridium attenuates
local or systemic inflammation in SSc (through effects
on T regulatory cells), therapy aimed at increasing the
abundance or activity of species in this genus may
improve SSc disease activity.
In contrast, Prevotella was more abundant in patients
with more severe GIT symptoms (bloating/distention
domain, diarrhoea domain scores). This genus appears
to have effects on intestinal T helper 17 cells,26 and it
has been found to be increased in faecal samples from
patients with CD,27 28 and new-onset rheumatoid
arthritis.29
Also consistent with our prior study, the abundance of
the pathobiont genera, Fusobacterium, and uncommon
γ-Proteobacteria (eg, Erwinia) were higher in the UCLA-SSc
faecal samples compared with controls. Fusobacterium
species are increased in patients with CD compared with
healthy controls and have been mechanistically proven to
enhance proinflammatory responses.30 31
We are intrigued by the increase of Lactobacillus in the
UCLA-SSc and OUH-SSc cohorts compared with healthy
controls. This finding has been observed now in three
different SSc cohorts (UCLA (colonic lavage specimens,
faecal specimens), OUH (faecal specimens), Swedish
cohort (faecal specimens)).10 32 We do not attribute this
expansion to probiotic use. First, due to the exception-
ally larger scale of the intestinal microbiome, ingestion
of lactobacillus-bearing probiotics does not measurably
alter faecal microbial composition.33 Second, very few
patients in the present cohorts were taking probiotics on
a regular basis, and none were taking probiotics within
3 weeks of the stool collection. Deemed a beneficial
commensal genus by several host inflammatory and
physiological end points in animal models, its abun-
dance is typically reduced in chronic inflammatory
human diseases..34 We further note that members of this
genus and their products alter the broader intestinal
microbial ecosystem gene expression and function,
which may be an intermediary of their action on sys-
temic host phenotypes.33 35 Since many patients with
SSc consume commercial probiotic supplements that
commonly include Lactobacillus species, the utility of
Lactobacillus as a biomarker or potential intervention in
patients deficient for this genus warrants further study.
The overall extent of dysbiosis appeared greatest in
the patients with SSc from UCLA compared with
patients with SSc from the OUH cohort. Possible expla-
nations for this disparity include different SSc pheno-
types between the cohorts. For instance, more patients
with SSc in the UCLA cohort had ILD than in the OUH
cohort. Accumulating evidence suggests that GIT micro-
biota plays a central role in regulating immune
Figure 5 Bacterial taxa associated with GIT disease score
and domains. Patients were dichotomised into low
(none-to-mild) or high (moderate to severe) disease severity
groups for the total GIT 2.0 score and its individual domains
(constipation, diarrhoea or distension/bloating). DESeq2
multivariate analysis was used to identify microbial taxa
significantly associated with low versus high groups (online
supplementary table S1), and calculate the fold change
between groups. Negative fold change scores (log2) denote
organisms decreased in high disease severity groups;
whereas, positive fold change scores denote organisms
increased in high disease severity groups. Legend provides
colour code of bacterial taxa at the phylum level; ‘f” denotes
family-level taxa. The size of the coloured dots represents the
square root of the absolute mean counts of the OTUs at the
genus level. DESeq2, differential expression analysis for
sequence count data; GIT, gastrointestinal tract; OUT,
operational taxonomic unit.
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responses in pulmonary disease, such as asthma.36 It is
possible that patients with SSc-ILD have distinct micro-
biota features compared with patients with SSc without
ILD. Indeed, a recent analysis by Andréaasen et al32
found that among patients with SSc from a single-centre
cohort, the extent of GIT dysbiosis was more severe in
patients with ILD compared with patients without ILD.
Furthermore, although there was a similar ratio of
patients with diffuse versus limited cutaneous disease in
each SSc cohort, there may have been subtle differences
in the peak severity of cutaneous sclerosis between the
two cohorts.
In addition to SSc disease phenotype, genetic variation
may account for some of the observed differences in
severity of dysbiosis between the two SSc cohorts. The
majority of the OUH-SSc cohort was Caucasian with a
genetic Norwegian background; whereas the UCLA
cohort was more ethnically diverse. A study for ulcerative
colitis reported that ethnicity stratifies a small propor-
tion (7.5%) of observed variation in β diversity.37 Dietary
variation may also contribute to the differences observed
between the two SSc cohorts.
In contrast with a prior research,32 38 faecal calprotec-
tin concentrations were not elevated in the majority of
patients with SSc (from the UCLA cohort), although dif-
ferent kits/protocols may have been used in prior
studies. While accumulating evidence suggests that
faecal calprotectin is seen in inflammatory intestinal dis-
eases (eg, IBD, colorectal cancer), future studies are
needed to determine whether this protein is a marker of
disease activity or the extent of dysbiosis in SSc.
The findings of the present study should be considered
within the context of certain limitations. First, the
present study is cross-sectional. It is unclear whether the
relationships observed between specific genera and GIT
symptoms are causational and/or persist with time.
Second, the sample size for both SSc cohorts is small.
Despite the small sample size, we observed several signifi-
cant associations consistent with the associations reported
in our prior study,10 suggesting that the present findings
are unlikely to be due to chance alone. Third, the same
healthy control cohort was used for the UCLA and
OUH-SSc cohorts. It may have been more ideal to use a
Norwegian healthy control cohort for the OUH-SSc ana-
lyses to control for genetic and dietary variation.
In addition, it may be prudent to include a measure of
GIT transit in future SSc-GIT microbiome studies. This
study did not assess GIT transit as there is no valid
measure of GIT transit in SSc; however, diarrhoea and con-
stipation are intrinsically related to GIT transit. Future
studies of this nature may consider using potential surro-
gate measures of GIT transit, such as wireless capsule
endoscopy. Finally, although it is a challenge to quantify
dietary patterns due to patient recall bias, future studies
could also consider the impact of diet on microbial com-
position in SSc. Accordingly, a distinct study design will be
required to assess the differential microbiota associated
with disease state or phenotypic progression.
The present study also has important strengths. By
studying two independent SSc cohorts, we have mini-
mised the risk of type 1 error that often ensues in discov-
ery cohort analyses of this nature. In addition, by
performing all of the sequencing analyses simultan-
eously, we have eliminated the possibility of a batch
effect. We also took substantial caution to ensure that all
patients withheld medications, such as antibiotics and
probiotics, at least 3 weeks prior to the stool collection,
by verifying medication lists three times in the month
preceding the collection.
To conclude, this study identified bacterial genera asso-
ciated with SSc using sophisticated sequencing analyses
of faecal specimens. Many of the genus-level gains and
losses appreciated in the faecal specimens examined in
the present study were also observed in our prior study
using colonic-mucosal specimens from the same patients
with SSc (but different control patients).10 Using two
independent SSc cohorts, this study also uncovered rela-
tionships between specific genera and severity of SSc-GIT
symptoms, which merit further investigation. While
larger studies are needed to validate and expand on
these findings, the present study is the first to character-
ise the lower GIT microbiota in two geographically and
ethnically distinct SSc cohorts.
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